Biomarkers have been shown to improve drug approval rates by 2-10x. As a leading multi-omics CRO, we help you scale your biomarker discovery capacity beyond genomics, enabling large-scale identification, validation, and translation of dynamic biomarkers for precision-guided drug development.
Thousands of metabolites, lipids, and proteins can be captured per sample, across thousands of samples at a time, scaling down to single quantitative measures.
From early discovery to clinical development, we off expert data interpretation to deliver outputs made to act on – and supporting efficient advancement of robust targets and biomarkers through the R&D pipeline.
Our multi-omics CRO services are disease- and drug modality-agnostic, spanning the entire drug development spectrum from profiling cells and media, to preclinical models, through to clinical implementation in Phase I, II, III and even Phase IV programs.
Our technologies and approaches can be applied in many different ways to de-risk development and accelerate promising drugs, with the ultimate goal of identifying biomarkers that can be used to align the right patient, with the right disease, with the right therapy.
Key research areas we support include:
Uncover dynamic tumor biology and biomarkers of immune states, response, and resistance across discovery through clinical development.
Decode metabolic and protein signatures to understand heterogeneity, risk, and treatment response in cardiometabolic disease.
Capture human‑relevant CNS disease biology using multi‑omics to measure established and novel biomarkers in blood and CSF.
Profile immune‑driven biology to identify biomarkers of disease progression, patient stratification, and therapeutic response.
Go beyond the genome to capture the systemic effects of genetically-driven rare diseases via dynamic protein, metabolite, lipid, and cytokine markers.
